Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Katti Jessen, L. Kessler, J. Kucharski, X. Guo, J. Staunton, M. Janes, M. Elia, U. Banerjee, L. Lan, S. Wang, J. Stewart, A. Luzader, L. Darjania, L.Li, K. Chan, M. Martin, P. Ren, C. Rommel, Y.Liu | ||||||||||||
Title | Abstract A171: A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. | ||||||||||||
|
|||||||||||||
URL | http://mct.aacrjournals.org/content/10/11_Supplement/A171.short | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mutant | Advanced Solid Tumor | sensitive | Serabelisib | Preclinical | Actionable | In a preclinical study, MLN1117 inhibited proliferation of tumor cells harboring oncogenic PIK3CA mutations in culture and inhibited tumor growth in PIK3CA mutant xenograft models (Cancer Ther 2011;10(11 Suppl):Abstract nr A171). | detail... |